DAWN missed EPS expectations by 35.57%
Feb 24, 2026, 11:36 PM
0.00%
What does DAWN do
Day One Biopharmaceuticals, based in Brisbane, California, focuses on developing cancer treatments, including its lead candidate tovorafenib. The company went public on May 27, 2021, and employs 174 people.
Day One Biopharmaceuticals (DAWN) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Day One Biopharmaceuticals's actual EPS was -$0.21, missing the estimate of -$0.15 per share, resulting in a -35.57% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.